Kanlioz, MuratEkici, UgurTatli, FaikKaratas, Turgay2024-08-042024-08-0420201530-45151534-4908https://doi.org/10.1097/SLE.0000000000000829https://hdl.handle.net/11616/99654Background: To evaluate the results obtained from the combination of intragastric botulinum toxin A (IGBTA), intragastric balloon (IGB), and IGBTA(+)IGB in the treatment of obesity. Materials and Methods: Three separate treatment groups were set up. IGBTA, IGB, and IGBTA(+)IGB were administered to Group 1, 2, and 3, respectively. The body mass indexes (BMI) of patients were measured before and 6 months after the treatment. The intragroup and intergroup treatment results have been evaluated. PResults: The mean BMI decreased by 1.6 kg/m(2) in 40 patients who received IGBTA in group 1 (P<0.001), 3.95 kg/m(2) in 42 patients who received IGB in group 2 (P<0.001), and 4.9 kg/m(2) in 39 patients who received IGBTA and IGB in group 3 (P<0.001) after 6 months of treatment. The intolerance because of the application was the highest in group 3, followed by group 2. Conclusion: The treatment was most successful in group 3 followed by group 2 and group 1, respectively. The authors recommend the group 3 treatment, provided that nausea, vomiting, and flatulence have a high index of probability in such a treatment. However, when deciding between group 1 and group 2 treatments, the authors recommend opting for group 2 treatment that shows to be more efficient.eninfo:eu-repo/semantics/closedAccessgastric balloongastric botulinum toxinobesity and obesity treatmentbariatric endoscopybody mass indexArticle3065005033274047610.1097/SLE.00000000000008292-s2.0-85097113173Q2WOS:000599708300007Q3